

Reference (include title, author, journal title, year of publication, volume and issue, pages)	Evidence level (I-VII)	Key findings, outcomes or recommendations
<p>American Academy of Pediatrics 2014, <i>Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection</i> accessed 16/07/1  <a href="http://pediatrics.aappublications.org/content/pediatrics/134/2/415.full.pdf">http://pediatrics.aappublications.org/content/pediatrics/134/2/415.full.pdf</a></p>	VII	<ul style="list-style-type: none"> <li>• Policy statement are evidenced based and reviewed every 3 years. Evidence is obtained from a systematic review of all recent and older peer reviewed literature relating to RSV disease in infants.</li> <li>• outlines the recommended high risk infant criteria</li> <li>• Outlines recommended time intervals and length of RSV treatment. 15mg/kg per dose during RSV season up to a maximum of 5 doses</li> </ul>
<p>Australian Medicines Handbook Pty Ltd 2018, <i>Palivizumab – Australian Medicines Handbook (online)</i>, accessed 16/07/18  <a href="https://amhonline.amh.net.au.acs.hcn.com.au/chapters/anti-infectives/antivirals/other-antivirals/palivizumab">https://amhonline.amh.net.au.acs.hcn.com.au/chapters/anti-infectives/antivirals/other-antivirals/palivizumab</a></p>	II	<ul style="list-style-type: none"> <li>• outlines Indications for RSV</li> <li>• provides evidence from 2 randomised control trials that Palivizumab reduced the rate of hospitalisation due to RSV infection in the identified cohort of infants</li> <li>• Provides guideline for a dosage of 15 mg/kg given Intramuscularly in the anterolateral thigh 4weekly</li> <li>• Identifies the splitting the palivizumab dose into 2 (or more) injections if the volume is &gt;1ml</li> </ul>

<p>Elia,S (2016) <i>Immunisation Service – RSV Immunoglobulin Report – November 2016</i> The Royal Children’s Hospital Melbourne</p>	<p>VII</p>	<ul style="list-style-type: none"> <li>• Provides results including data of number of inpatients and outpatients who received Palivizumab during the 2016 season</li> <li>• Provides data of RSV admissions to RCH in2016 RSV season</li> <li>• Provides data on cost saving on vial sharing of Palivizumab vials</li> </ul>
<p>National Health and Medical Research Council 2017, <i>The Australian Immunisation Handbook</i> accessed16/07/17&lt;<a href="http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/content/home~handbook10part5~handbook10-5-1">http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/content/home~handbook10part5~handbook10-5-1</a></p>	<p>VII</p>	<ul style="list-style-type: none"> <li>• Evidence is based from systematic reviews and best available scientific evidence</li> <li>• Outlines indications of high risk infants</li> <li>• Identifies that Palivizumab has been shown to decrease hospitalisation of children at risk of RSV disease from approximately 10 % to approximately 5%</li> <li>• Provides guideline for a dosage of 15 mg/kg given Intramuscularly in the anterolateral thigh 4weekly</li> </ul>